デフォルト表紙
市場調査レポート
商品コード
1463112

トラコーマ治療市場、シェア、規模、動向、産業分析レポート：投与経路別、薬剤クラス別、地域別、セグメント別予測、2024年～2032年

Trachoma Treatment Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral and Topical); By Drug Class; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 119 Pages
納期
即日から翌営業日
カスタマイズ可能
トラコーマ治療市場、シェア、規模、動向、産業分析レポート：投与経路別、薬剤クラス別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のトラコーマ治療市場規模は2032年までに9億2,443万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

トラコーマの有病率の急速な増加や、トラコーマとその治療オプションに関する一般市民の認識を高めるための民間および公的ヘルスケア組織間での普及は、市場成長を促進する顕著な要因です。例えば、2024年1月、活動性トラコーマの有病率が高い地区に住む人々の数は、2023年には約1億1,600万人と推定され、150万人以上が睫毛乱生症の手術を必要としています。

さらに、予防可能な失明の蔓延を抑制するために、新しいトラコーマ治療法の開発を促進する有利な規制政策やインセンティブ・プログラムが世界中で増加しており、市場の成長をさらに後押ししています。例えば、2024年2月、連邦政府は、トラコーマ、マラリア、フィラリア症、オンコセルカ症、ゲーレムス症を含む疾病を撲滅するための新プログラムの開始を発表しました。

さらに、トラコーマはMEAやAPAC地域の低開発経済諸国や発展途上国で最も蔓延しているため、ヘルスケア・インフラの大幅な改善に対するニーズが高まっており、世界・ヘルスケア企業がこれらの新興市場や未開拓市場でプレゼンスを拡大することを後押ししています。企業や政府がヘルスケア・インフラ整備への投資を増やし、より多くの患者がヘルスケア・サービスに容易にアクセスできるようにすることで、効果的なトラコーマ治療オプションに対する需要は飛躍的に高まると思われます。例えば、国際貿易庁によると、2024年1月、マレーシア政府はヘルスケア部門の強化を継続し、ヘルスケアに対する国家予算を2022年の710万米ドルから790万米ドルに増額しました。

トラコーマの遠隔診断・治療を可能にするデジタルヘルス技術と遠隔医療が世界中で台頭しており、トラコーマ治療ソリューションを提供する企業にとって有利な機会をもたらしています。また、衛生・公衆衛生ソリューションや、従来のソリューションと比較して投与が容易で手頃な価格の新薬など、トラコーマ予防のための製品開拓に注力している企業は、市場で競争優位に立つ可能性が高いです。

トラコーマ治療市場レポートハイライト

経口薬セグメントが注目すべきシェアを占めたが、これは全身的な適用範囲、汚染リスクの低減、東方投与などの特徴によるものです。

マクロライド系薬剤は、手頃な価格、耐性菌の減少、入手の容易さ、治療期間の短さなどの特徴から、大きなシェアを占めています。

北米は、確立されたヘルスケアインフラと新たなソリューション開発のための研究開発活動の高まりにより、世界市場を席巻しています。

主な市場プレイヤーは、Allergan Inc.、Eli Lilly and Company、Bayer AG、Bausch Health Companies、Cipla、Novartis AG、Arbor Pharmaceuticals、AbbVieなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のトラコーマ治療市場の洞察

  • トラコーマ治療市場- 業界スナップショット
  • トラコーマ治療市場力学
    • 促進要因と機会
      • トラコーマの蔓延と疾病予防に関する意識の高まりが成長を促進
      • ヘルスケア費の改善と治療法の進歩が市場の成長を後押し
    • 抑制要因と課題
      • 治療にかかる高額な費用と認識不足
  • PESTLE分析
  • トラコーマ治療業界の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 投与経路別の世界市場

  • 主な調査結果
  • イントロダクション
  • 経口
  • 外用

第6章 薬剤クラス別の世界市場

  • 主な調査結果
  • イントロダクション
  • マクロライド
  • テトラサイクリン
  • 眼科用抗感染薬
  • スルホンアミド

第7章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • トラコーマ治療市場の評価、地域別、2019-2032年
  • トラコーマ治療市場-北米
    • 北米：トラコーマ治療市場、薬剤クラス別、2019年～2032年
    • 北米：トラコーマ治療市場、投与経路別、2019年～2032年
    • トラコーマ治療市場-米国
    • トラコーマ治療市場- カナダ
  • トラコーマ治療市場- 欧州
    • 欧州：トラコーマ治療市場、薬剤クラス別、2019年～2032年
    • 欧州：トラコーマ治療市場、投与経路別、2019年～2032年
    • トラコーマ治療市場- 英国
    • トラコーマ治療市場- フランス
    • トラコーマ治療市場- ドイツ
    • トラコーマ治療市場- イタリア
    • トラコーマ治療市場- スペイン
    • トラコーマ治療市場- オランダ
    • トラコーマ治療市場- ロシア
  • トラコーマ治療市場- アジア太平洋地域
    • アジア太平洋地域：トラコーマ治療市場、薬剤クラス別、2019年～2032年
    • アジア太平洋地域：トラコーマ治療市場、投与経路別、2019年～2032年
    • トラコーマ治療市場- 中国
    • トラコーマ治療市場- インド
    • トラコーマ治療市場- マレーシア
    • トラコーマ治療市場- 日本
    • トラコーマ治療市場- インドネシア
    • トラコーマ治療市場- 韓国
  • トラコーマ治療市場-中東およびアフリカ
    • 中東およびアフリカ：トラコーマ治療市場、薬剤クラス別、2019-2032年
    • 中東およびアフリカ：トラコーマ治療市場、投与経路別、2019-2032年
    • トラコーマ治療市場- サウジアラビア
    • トラコーマ治療市場-UAE
    • トラコーマ治療市場- イスラエル
    • トラコーマ治療市場- 南アフリカ
  • トラコーマ治療市場-ラテンアメリカ
    • ラテンアメリカ：トラコーマ治療市場、薬剤クラス別、2019年～2032年
    • ラテンアメリカ：トラコーマ治療市場、投与経路別、2019年～2032年
    • トラコーマ治療市場- メキシコ
    • トラコーマ治療市場- ブラジル
    • トラコーマ治療市場- アルゼンチン

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第9章 企業プロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Allergan Inc
  • Arbor Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Bayer AG.
  • Cipla Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
図表

List of Tables

  • Table 1 Global Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 2 Global Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 3 Trachoma Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 5 North America: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 6 U.S.: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 U.S.: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 8 Canada: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 9 Canada: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 10 Europe: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 11 Europe: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 12 UK: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 13 UK: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 14 France: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 15 France: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 16 Germany: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 17 Germany: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 18 Italy: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 Italy: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 20 Spain: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 21 Spain: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 22 Netherlands: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 23 Netherlands: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 24 Russia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 25 Russia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 28 China: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 29 China: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 30 India: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 India: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 32 Malaysia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 33 Malaysia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 34 Japan: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 35 Japan: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 36 Indonesia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 37 Indonesia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 38 South Korea: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 39 South Korea: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 44 UAE: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 45 UAE: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 46 Israel: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 47 Israel: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 48 South Africa: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 49 South Africa: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 50 Latin America: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 51 Latin America: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 52 Mexico: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 53 Mexico: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 54 Brazil: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 Brazil: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 56 Argentina: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 57 Argentina: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global Trachoma Treatment Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Drug Class
  • Figure 7 Global Trachoma Treatment Market, by Drug Class, 2022 & 2032 (USD Million)
  • Figure 8 Market by Route of Administration
  • Figure 9 Global Trachoma Treatment Market, by Route of Administration, 2022 & 2032 (USD Million)
  • Figure 10 Trachoma Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - Trachoma Treatment Market
目次
Product Code: PM4785

The global trachoma treatment market size is expected to reach USD 924.43 million by 2032, according to a new study by Polaris Market Research. The report "Trachoma Treatment Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral and Topical); By Drug Class; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rapid increase in the prevalence of trachoma and its proliferation among private and public healthcare organizations to raise awareness about trachoma and its treatment options among the general public are prominent factors driving the market growth. For instance, in January 2024, the number of people living in districts with a high prevalence of active trachoma was estimated at around 116 million in 2023, and over 1.5 million people required surgery for trichiasis.

In addition, a growing number of favorable regulatory policies and incentive programs promoting the development of new trachoma treatments to control the spread of preventable blindness worldwide, further boosting market growth. For instance, in February 2024, The Federal government announced the launch of its new program to eliminate diseases, including trachoma, malaria, filariasis, onchocerciasis, and goehelminthiasis

Furthermore, as trachoma is most prevalent is under-developed or developing economies of MEA and APAC region, thereby the need for significant improvements in healthcare infrastructure is growing and encouraging global healthcare companies to expand their market presence in these emerging and untapped markets. With companies and governments increasingly investing in healthcare infrastructure development and making healthcare services easily accessible to a larger patient population, the demand for effective trachoma treatment options will boost drastically. For instance, according to the International Trade Administration, in January 2024, the Malaysian government continued to strengthen its healthcare sector, increasing the national budget for healthcare to USD 7.9 million compared to USD 7.1 million in 2022.

The emergence of digital health technologies and telemedicine across the globe, which enables the remote diagnosis and treatment of trachoma, is presenting a lucrative opportunity for companies providing trachoma treatment solutions. Also, companies focusing on the development of products for trachoma prevention including hygiene and sanitation solutions and new drugs that are easy to administer and affordable as compared to conventional solutions, are likely to gain a competitive edge in the market.

Trachoma Treatment Market Report Highlights

Oral segment accounted for a noteworthy share, which is attributed to its characteristics, including systemic coverage, reduced contamination risk, and east administration

The macrolides segment held a significant share due to its affordability, reduced resistance, easy availability, and shorter treatment time

North America dominated the global market on account of well-established healthcare infrastructure and rising R&D activities for the development of new solutions

The key market players include Allergan Inc., Eli Lilly and Company, Bayer AG, Bausch Health Companies, Cipla, Novartis AG, Arbor Pharmaceuticals, and AbbVie

Polaris Market Research has segmented the trachoma treatment market report based on route of administration, drug class, and region:

Trachoma Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Topical

Trachoma Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Macrolides
  • Tetracycline
  • Ophthalmic Anti-Infective
  • Sulfonamides

Trachoma Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Trachoma Treatment Market Insights

  • 4.1. Trachoma Treatment Market - Industry Snapshot
  • 4.2. Trachoma Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of trachoma and awareness about disease prevention to drive growth
      • 4.2.1.2. Improvements in healthcare expenditure and advancements in treatments to boost market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost associated with treatment and lack of awareness
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Trachoma Treatment Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Trachoma Treatment Market, by Route of Administration

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Trachoma Treatment, by Route of Administration, 2019-2032 (USD Million)
  • 5.3. Oral
    • 5.3.1. Global Trachoma Treatment Market, by Oral, by Region, 2019-2032 (USD Million)
  • 5.4. Topical
    • 5.4.1. Global Trachoma Treatment Market, by Topical, by Region, 2019-2032 (USD Million)

6. Global Trachoma Treatment Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • 6.3. Macrolides
    • 6.3.1. Global Trachoma Treatment Market, by Macrolides, by Region, 2019-2032 (USD Million)
  • 6.4. Tetracycline
    • 6.4.1. Global Trachoma Treatment Market, by Tetracycline, by Region, 2019-2032 (USD Million)
  • 6.5. Ophthalmic Anti-infective
    • 6.5.1. Global Trachoma Treatment Market, by Ophthalmic Anti-infective, by Region, 2019-2032 (USD Million)
  • 6.6. Sulfonamides
    • 6.6.1. Global Trachoma Treatment Market, by Sulfonamides, by Region, 2019-2032 (USD Million)

7. Global Trachoma Treatment Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Trachoma Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. Trachoma Treatment Market - North America
    • 7.3.1. North America: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 7.3.2. North America: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.3.3. Trachoma Treatment Market - U.S.
      • 7.3.3.1. U.S.: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.3.4. Trachoma Treatment Market - Canada
      • 7.3.4.1. Canada: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.4. Trachoma Treatment Market - Europe
    • 7.4.1. Europe: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 7.4.2. Europe: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.3. Trachoma Treatment Market - UK
      • 7.4.3.1. UK: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.3.2. UK: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.4. Trachoma Treatment Market - France
      • 7.4.4.1. France: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.4.2. France: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.5. Trachoma Treatment Market - Germany
      • 7.4.5.1. Germany: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.6. Trachoma Treatment Market - Italy
      • 7.4.6.1. Italy: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.7. Trachoma Treatment Market - Spain
      • 7.4.7.1. Spain: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.8. Trachoma Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.4.9. Trachoma Treatment Market - Russia
      • 7.4.9.1. Russia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.5. Trachoma Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.5.3. Trachoma Treatment Market - China
      • 7.5.3.1. China: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.5.3.2. China: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.5.4. Trachoma Treatment Market - India
      • 7.5.4.1. India: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.5.4.2. India: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.5.5. Trachoma Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.5.6. Trachoma Treatment Market - Japan
      • 7.5.6.1. Japan: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.5.7. Trachoma Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.5.8. Trachoma Treatment Market - South Korea
      • 7.5.8.1. South Korea: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.6. Trachoma Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.6.3. Trachoma Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.6.4. Trachoma Treatment Market - UAE
      • 7.6.4.1. UAE: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.6.5. Trachoma Treatment Market - Israel
      • 7.6.5.1. Israel: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.6.6. Trachoma Treatment Market - South Africa
      • 7.6.6.1. South Africa: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.7. Trachoma Treatment Market - Latin America
    • 7.7.1. Latin America: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 7.7.2. Latin America: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.7.3. Trachoma Treatment Market - Mexico
      • 7.7.3.1. Mexico: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.7.4. Trachoma Treatment Market - Brazil
      • 7.7.4.1. Brazil: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 7.7.5. Trachoma Treatment Market - Argentina
      • 7.7.5.1. Argentina: Trachoma Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: Trachoma Treatment Market, by Route of Administration, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Abbott Laboratories
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. AbbVie Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Allergan Inc
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Arbor Pharmaceuticals Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Bausch Health Companies Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Bayer AG.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Cipla Inc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Eli Lilly and Company
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. F. Hoffmann-La Roche Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Merck & Co. Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Mylan NV
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Novartis AG
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Pfizer Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Sanofi SA
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development